Stem Cell Therapeutic and Research Reauthorization Act of 2015

Bill 114 hr 2820, also known as the Stem Cell Therapeutic and Research Reauthorization Act of 2015, is a piece of legislation that aims to reauthorize and continue funding for stem cell research and therapy programs in the United States. The bill was introduced in the House of Representatives on June 18, 2015 by Rep. Chris Smith (R-NJ) and referred to the House Committee on Energy and Commerce.

The main purpose of the bill is to support and advance research on the potential medical benefits of stem cells, which have shown promise in treating a variety of diseases and conditions. The bill seeks to reauthorize the Stem Cell Therapeutic and Research Act of 2005, which established the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory.

If passed, the bill would provide funding for the continued operation of these programs, as well as for research grants and clinical trials related to stem cell therapy. The bill also includes provisions to ensure that stem cell research is conducted ethically and in accordance with federal regulations. Overall, the Stem Cell Therapeutic and Research Reauthorization Act of 2015 aims to support and promote the development of stem cell therapies that have the potential to improve the health and well-being of individuals suffering from a wide range of medical conditions.